Eyenovia (Nasdaq:EYEN) announced today that it is developing a microdosing system to facilitate the digital delivery of eye medications. New York-based Eyenovia develops a pipeline of late-stage microdose array print (MAP) therapeutics. It aims for this system to improve the overall patient experience and streamline practice flow. The investigational device showed promise in delivery cleaner […]
Optical/Ophthalmic
Glaukos beats The Street in Q3
Glaukos (NYSE:GKOS) shares hardly shifted on third-quarter results that came in ahead of the consensus forecast. The Aliso Viejo, California-based ophthalmic implant maker posted losses of $27.6 million in the quarter. That amounts to 58¢ per share on sales of $71.3 million for the three months ended Sept. 30, 2022. Glaukos registered a deep bottom-line […]
5 top ophthalmic device innovations you need to know
Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye. Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old […]
Phase 3 trial data support Glaukos iDose eye drop alternative
Glaukos (NYSE:GKOS) today announced positive outcomes from two Phase 3 pivotal trials for its iDose TR system. iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP). Glaukos designed it to continuously release therapeutic levels of medication for at least one year. Once all travoprost is released, iDose […]
Second Sight Medical merges with Nano Precision Medical, rebrands as Vivani Medical
Second Sight Medical (Nasdaq:EYES) announced today that it completed its merger with Nano Precision Medical and rebranded. In February, the two companies entered into a definitive agreement under which Nano Precision Medical (NPM) would merge with a wholly-owned subsidiary of Second Sight in an all-stock transaction, with NPM as the surviving company under Second Sight’s […]
AbbVie enters partnership with iStar with option to acquire
AbbVie (NYSE:ABBV) announced today that it entered into a strategic alliance with iStar Medical over the MINIject device. The strategic transaction centers around helping to further develop and commercialize iStar’s MINIject minimally invasive glaucoma surgical (MIGS) device. It will also provide AbbVie with a chance to expand its eye care business through an option to […]
Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment
Alcon (NYSE:ACL) announced today that it agreed to acquire Eysuvis pharmaceutical eye drops from Kala Pharmaceuticals. Geneva, Switzerland-based Alcon will pay $60 million upfront to Kala for the dry eye treatment. As part of the agreement, the company will also acquire Kala’s Inveltys corticosteroid for twice-per-day treatment of post-operative inflammation and pain following ocular surgery. […]
Johnson & Johnson Vision wins Fast Company award for drug-eluting contact lens
Johnson & Johnson Vision announced today that it was named a winner of Fast Company’s 2022 World Changing Ideas Awards. The eye health business arm of Johnson & Johnson (NYSE: JNJ) received the award in the “Wellness” category for its Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen). The drug-eluting contact, which provides […]
Bausch + Lomb, Clearside Biomedical launch Xipere in U.S.
Bausch Health’s (NYSE:BHC) Bausch + Lomb and Clearside Biomedical (Nasdaq:CLSD) launched their Xipere product in the U.S. today. Clearside Biomedical designed the Xipere triamcinolone acetonide suprachoroidal injectable suspension therapy with a proposed indication for treating macular edema associated with uveitis, a form of eye inflammation. Xipere works with Clearside’s proprietary SCS Microinjector to deliver the […]
Johnson & Johnson is bringing the world’s first drug-eluting contact lens to market
Johnson & Johnson has a potential alternative to eye drops with its drug-eluting Acuvue Theravision contact lens. As far back as the early 1960s, researchers toyed with the idea of delivering medication through contact lenses. Johnson & Johnson Vision (NYSE:JNJ) Director of Clinical Science Dr. Brian Pall told Drug Delivery Business News that patents back then […]
